U.S. markets close in 3 hours 46 minutes
  • S&P 500

    3,753.40
    -29.88 (-0.79%)
     
  • Dow 30

    30,024.69
    -249.18 (-0.82%)
     
  • Nasdaq

    11,084.81
    -63.83 (-0.57%)
     
  • Russell 2000

    1,754.06
    -8.63 (-0.49%)
     
  • Crude Oil

    88.17
    +0.41 (+0.47%)
     
  • Gold

    1,716.80
    -4.00 (-0.23%)
     
  • Silver

    20.50
    -0.05 (-0.24%)
     
  • EUR/USD

    0.9794
    -0.0090 (-0.91%)
     
  • 10-Yr Bond

    3.8120
    +0.0530 (+1.41%)
     
  • GBP/USD

    1.1125
    -0.0196 (-1.73%)
     
  • USD/JPY

    145.0410
    +0.4310 (+0.30%)
     
  • BTC-USD

    20,021.05
    -28.93 (-0.14%)
     
  • CMC Crypto 200

    455.63
    -7.50 (-1.62%)
     
  • FTSE 100

    6,997.27
    -55.35 (-0.78%)
     
  • Nikkei 225

    27,311.30
    +190.80 (+0.70%)
     

Shareholders in Werewolf Therapeutics (NASDAQ:HOWL) are in the red if they invested a year ago

·2 min read

While not a mind-blowing move, it is good to see that the Werewolf Therapeutics, Inc. (NASDAQ:HOWL) share price has gained 22% in the last three months. But that's small comfort given the dismal price performance over the last year. Specifically, the stock price slipped by 61% in that time. It's not that amazing to see a bounce after a drop like that. It may be that the fall was an overreaction.

Now let's have a look at the company's fundamentals, and see if the long term shareholder return has matched the performance of the underlying business.

Check out our latest analysis for Werewolf Therapeutics

Because Werewolf Therapeutics made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. Shareholders of unprofitable companies usually expect strong revenue growth. That's because it's hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit.

You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image).

earnings-and-revenue-growth
earnings-and-revenue-growth

If you are thinking of buying or selling Werewolf Therapeutics stock, you should check out this FREE detailed report on its balance sheet.

A Different Perspective

Werewolf Therapeutics shareholders are down 61% for the year, even worse than the market loss of 8.9%. That's disappointing, but it's worth keeping in mind that the market-wide selling wouldn't have helped. It's great to see a nice little 22% rebound in the last three months. This could just be a bounce because the selling was too aggressive, but fingers crossed it's the start of a new trend. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Consider for instance, the ever-present spectre of investment risk. We've identified 5 warning signs with Werewolf Therapeutics (at least 1 which can't be ignored) , and understanding them should be part of your investment process.

Of course Werewolf Therapeutics may not be the best stock to buy. So you may wish to see this free collection of growth stocks.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here